Can-Fite BioPharma (CANF) EBITDA Margin Growth (1y) (2016 - 2023)
Can-Fite BioPharma (CANF) EBITDA Margin Growth (1y) (2016 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2,002.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 29,091.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -1,651.00 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -3,558.00 |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -27,400.00 |
| Sep 30, 2023 | 30,974.00 |
| Jun 30, 2023 | 10,450.00 |
| Mar 31, 2023 | -22,758.00 |
| Dec 31, 2022 | 106,528.00 |
| Sep 30, 2022 | 13,713.00 |
| Jun 30, 2022 | 23,849.00 |
| Mar 31, 2022 | 31,079.00 |
| Dec 31, 2021 | 39,416.00 |
| Sep 30, 2021 | -22,352.00 |
| Jun 30, 2021 | 62,474.00 |
| Mar 31, 2021 | 69,270.00 |
| Dec 31, 2020 | 3,290.00 |
| Sep 30, 2020 | -93,261.00 |
| Jun 30, 2020 | -25,429.00 |
| Mar 31, 2020 | -273,184.00 |
| Dec 31, 2019 | -153,547.00 |
| Sep 30, 2019 | -26,677.00 |
| Jun 30, 2019 | 28,116.00 |
| Mar 31, 2019 | 32,097.00 |